Cancer immunotherapy compositions and methods of use

Details Cancer immunotherapy compositions and methods of use Cancer immunotherapy compositions and methods of use

2011-04-05

2011-04-05

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S277100

Reexamination Certificate

active

07919079

ABSTRACT:
Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer.

REFERENCES:
patent: 5078996 (1992-01-01), Conlon, III et al.
patent: 5098702 (1992-03-01), Zimmerman et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5637483 (1997-06-01), Dranoff et al.
patent: 5686279 (1997-11-01), Finer et al.
patent: 5731190 (1998-03-01), Wickham et al.
patent: 5753500 (1998-05-01), Shenk et al.
patent: 5756086 (1998-05-01), McClelland et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5846767 (1998-12-01), Halpin et al.
patent: 5846782 (1998-12-01), Wickham et al.
patent: 5904920 (1999-05-01), Dranoff et al.
patent: 5922315 (1999-07-01), Roy
patent: 5985290 (1999-11-01), Jaffee et al.
patent: 6033674 (2000-03-01), Jaffee et al.
patent: 6040183 (2000-03-01), Ferrari et al.
patent: 6057155 (2000-05-01), Wickham et al.
patent: 6093570 (2000-07-01), Ferrari et al.
patent: 6117425 (2000-09-01), MacPhee et al.
patent: 6127525 (2000-10-01), Crystal et al.
patent: 6187306 (2001-02-01), Pardoll et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6350445 (2002-02-01), Jaffee et al.
patent: 6464973 (2002-10-01), Levitsky et al.
patent: 6548286 (2003-04-01), Samulski et al.
patent: 6555368 (2003-04-01), Curiel
patent: 6602503 (2003-08-01), Lobb et al.
patent: 6623940 (2003-09-01), Ledbetter et al.
patent: 6683170 (2004-01-01), Curiel et al.
patent: 6692736 (2004-02-01), Yu et al.
patent: 6984720 (2006-01-01), Korman et al.
patent: 2002/0168342 (2002-11-01), Wang et al.
patent: 2004/0265955 (2004-12-01), Fang et al.
patent: 2005/0002916 (2005-01-01), Jooss et al.
patent: WO 99/39734 (1999-08-01), None
patent: WO 00/67576 (2000-11-01), None
patent: WO 00/72686 (2000-12-01), None
patent: WO 03/066810 (2003-12-01), None
patent: WO 2004/113493 (2004-12-01), None
patent: WO 2005/017149 (2005-02-01), None
Elsas et al, J Exp Med, 1999, 190:355-366.
Shi et al, Cancer Gene Therapy, 1999, 6:81-88.
Griffin et al, J Immunol Methods, 2001, 248:77-90.
Zheng et al, PNAS, 1998, 95:6284-6289.
Allison, J,P., “Blockade of T Cell Inhibitory Signals: A New Paradigm in Tumor Immunotherapy?” Cancer Immunity, 5:9 (2005).
Altschul et al., “Basic Local Alignment Search Tool” J. Mol. Biol. 215:403-410 (1990).
Aoki et al., “Expression of Murine Interleukin 7 in a Murine Glioma Cell Line Results in Reduced Tumorigenicity in Vivo” PNAS 89(9):3850-3854 (1992).
Armstong et al., “Cytokine Modified Tumor Vaccines” Surgical Oncology Clin, N. AM. 11(3):681-696 (2002).
Batzer et al., “Enhanced Evolutionary PCR Using Oligonucleotides with Inosine at the 3′-Terminus” Nucleic Acid Res. 19(18): 5081 (1991).
Bett et al., “Packaging Capacity and Stability of Human Adenovius Type 5 Vectors” J. Virology 67:5911-5921 (1993).
Bodey et al., “Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy” 20:(4) 2665-2676 (2000).
Bossis and Chiorini, “Cloning of an Avian Adeno-Associated Virus (AAAV) and Generation of Recombinant AAAV Particles” J. Virol. 77(12):6799-6810 (2003).
Brunner et al., “CTLA-4-Mediated Inhibition of Early Events of T Cell Proliferation1” J. Immunology 162:5813-5820 (1999).
Chambers et al., “CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy” Annual Rev. Immunol. 19:565-594 (2001).
Chang et al., “Immunogenetic Therapy of Human Melanoma Utlizing Autologous Tumor Cells Transduced to Secrete Granulocyte-Macrophage Colony-Stimulating Factor” Human Gene Therapy 11:839-850 (2000).
Chaplin et al., “Production of Interleukin-12 as a Self-Processing 2A Polypeptide” J. Interferon Cytokine Res. 19:235-241 (1999.
Chu and Sharp, “SV40 DNA Transfection of Cells in Suspension: Analysis of the Efficiency of Transcription and Translation of T-antigen” Gene 13:197-202 (1981).
Darrow et al., “The Role of HLA Class I Antigens in Recognition of Melanoma Cells by Tumor-Specific Cytotoxic T Lymphocytes” J. Immunology 142:3329-3335 (1989).
de Felipe et al., Use of the 2A Sequence from Foot-and-Mouth Disease Virus in the Generation of Retroviral Vectors for Gene Therapy Gene Therapy 6:198-208 (1999).
de Felipe and Izquierdo, “Tricistronic and Tetracistronic Retroviral Vectors for Gene Transfer” Human Gene Therapy 11:1921-1931 (2000).
Donnelly et al., Analysis of the Aphthovirus 2A/2B Polyprotein ‘Cleavage’ Mechanism Indicates Not a Proteolytic Reaction, but a Novel Translational Effect: a Putative Ribosomal ‘Skip’ J. Gen. Virol. 82: 1013-1025 (2001).
Donnelly et al., “The Cleavage Activities of Foot and Mouth Disease Virus 2A Site-Directed Mutants and Naturally Occurring ‘2A-Like’ Sequences” J. Gen. Virol. 82: 1027-1041 (2001).
Dranoff et al., “Vaccination with Irradiated Tumor Cells Engineered to Secrete Murine Granulocyte-Macrophage Colony-Stimulating Factor Stimulates Potent, Specific, and Long-Lasting Anti-Tumor Immunity” PNAS USA 90:3539-3543(1993).
Dull et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System” J. Virol. 72: 8463-8471 (1998).
Dummer, R., “GVAX Cell Genesys” Curr. Opinion Investig. Drugs 2(6):844-848 (2001).
Emens et al., “Clinical Protocol” Human Gene Therapy 15:313-337 (2004).
Fearon et al., “Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Antitumor Response” Cell 60:397-403 (1990).
Fields Virology Third Edition, edited by B.N. Fields et al., Lippincott Raven Publisher (1996), Chapter 58, “Retrovirdae: The Viruses and Their Relication”, Classification, pp. 1768-1771, including Table 1.
Finer et al., “kat:A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes,”Blood, 83:43-50 (1994).
Gansbacher et al., “Retroviral Vector-Mediated γ-Interferon Gene Transfer into Tumor Cells Generates Potent and Long Lasting Antitumor Immunity,”Cancer Research50:7820-7825 (1990.
Gansbacher et al., “Interleukin 2 Gene Transfer Into Tumor Cells Abrogates Tumorigenicity and Induces Protective Immunity” J. Exp. Med. 172:1217-1224 (1990).
Gao et al., “Adeno-associated viruses undergo substantial evolution in primates during natural infections,”PNAS USA100:6081-6086 (2003).
Gao et al.,“Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy,”PNAS USA99:11854-11859 (2002).
Golumbeck et al., “Treatment of Established Renal Cancer of Tumor Cells Engineer to Secrete Interleukin-4,”Reports, 713-716 (1991).
Graham et al., “A new technique for the assay of infectivity of humans adenovirus 5,”Virology52:456-467 (1973).
Halpin et al., “Self-processing 2A-polyproteins—a system for co-ordinate expression of multiple proteins in transgenic plants,”The Plant Journal17:453-459 (1999.
Hartley and Rowe, “Naturally occurring murine leukemia viruses in wild mice: characterization of a new ‘amphotropic’ class,”J. Virol. 19:19-25 (1976).
Hock et al., “Interleukin 7 induces CD4+ T cell-dependent tumor rejection,”J. Exp. Med. 174:1291-1298 (1991).
Hom et al., “Common Expression of Melanoma Tumor-Associated Antigens Recognized by Human Tumor Infiltrating Lymphocytes: Analysis by Human Lymphocytes Antigen Restriction,”Immunother. 10:153-164 (1991).
Huang et al., “Role of bone marrow derived cells in presenting MHC class I restricted tumour antigens,”Science264:961-965

Affiliated with

Also associated with

Rating

Cancer immunotherapy compositions and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancer immunotherapy compositions and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer immunotherapy compositions and methods of use will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2653435